Antiparkinsonian agents and fluphenazine decanoate.
The author examined the incidence and severity of extrapyramidal symptoms (EPS) in 19 male psychotic outpatients receiving fluphenazine decanoate. Ten patients developed an EPS; only 3 had symptoms of the highest severity. The data suggest that neither prophylactic nor long-term use of antiparkinsonian agents is necessary for most patients receiving fluphenazine decanoate. On the basis of a comparison to a study of fluphenazine enanthate patients, the author concludes that fluphenazine decanoate is the drug of choice in terms of incidence and severity of EPS.
D000328:Adult; D000978:Antiparkinson Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D001480:Basal Ganglia Diseases / Q000139:chemically induced* / Q000188:drug therapy / Q000517:prevention & control; D003651:Decanoates / Q000009:adverse effects; D003865:Major Depressive Disorder / Q000188:drug therapy; D005476:Fluphenazine / Q000009:adverse effects*; D006537:Heptanoates / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D012559:Schizophrenia / Q000188:drug therapy
D000978:Antiparkinson Agents; D003651:Decanoates; D006537:Heptanoates; D005476:Fluphenazine